Clinical Trials Logo

Hyperlipoproteinemia clinical trials

View clinical trials related to Hyperlipoproteinemia.

Filter by:

NCT ID: NCT05256654 Active, not recruiting - Dyslipidemias Clinical Trials

A Study of LY3561774 in Participants With Mixed Dyslipidemia

PROLONG-ANG3
Start date: July 20, 2022
Phase: Phase 2
Study type: Interventional

This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.

NCT ID: NCT02933138 Completed - Clinical trials for Hyperlipoproteinemia

Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia

Start date: July 2010
Phase: N/A
Study type: Observational

Purpose: The mechanism of most of the multifactorial chylomicronemia (MCM) remains elusive. In order to decipher the mechanisms involved in the occurrence of this disease, plasma TG lipolysis characteristics will be monitored for 60 minutes after heparin injection instead of the 10 minutes gold standard, in a large group of genotyped MCM patients.

NCT ID: NCT01928342 Recruiting - Clinical trials for Hyperlipoproteinemia

The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia

Start date: March 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A (CoA) capsule, combined use with statin, in Chinese patients with moderate dyslipidemia.

NCT ID: NCT01878227 Completed - Clinical trials for Hyperlipoproteinemia

Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A capsule with a marketed drug, fenofibrate, in Chinese patients with moderate dyslipidemia.

NCT ID: NCT01811082 Completed - Clinical trials for Hyperlipoproteinemia

Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A capsule with a marketed drug, Pantethine Capsule, in Chinese patients with moderate dyslipidemia.

NCT ID: NCT01645046 Completed - Clinical trials for Hyperlipoproteinemia

The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A (CoA) capsule in Chinese patients with moderate dyslipidemia.

NCT ID: NCT01239992 Terminated - Metabolic Syndrome Clinical Trials

Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Start date: June 2011
Phase: Phase 4
Study type: Interventional

The study is designed to evaluate the effect of Niacin/Laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction and inflammation.

NCT ID: NCT01146522 Completed - Clinical trials for Hyperlipoproteinemia

Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia

Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess safety, tolerability, and effect of LCQ908 on blood lipids in patients with severe hypertriglyceridemia.

NCT ID: NCT01057654 Completed - Clinical trials for Hypercholesterolemia

A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin

Start date: January 1996
Phase: Phase 3
Study type: Interventional

Lifibrol is a new lipid-lowering drug which lowers cholesterol to an extent in the order of magnitude of the statins. The mechanism of action of this compound is different from the one of statins but remains unknown. The current study will investigate the mechanism of action using stable-isotope turnover methods. The study will be done in healthy male volunteers.

NCT ID: NCT00005128 Completed - Clinical trials for Cardiovascular Diseases

Lipid Research Clinics Population Studies

Start date: July 1972
Phase: N/A
Study type: Observational

To conduct epidemiologic surveys of the distribution, causes, and consequences of the dyslipoproteinemias. The Population Studies include the Prevalence Study, the Family Study, and the Mortality Follow-up Study and shared the same general population base.